[144] Amneal Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Amneal Pharmaceuticals (AMRX) Form 144 discloses a proposed sale of 33,436 Common Class A shares through Charles Schwab (3000 Schwab Way, Westlake, TX) with an aggregate market value of $304,100.00. The filing reports 314,079,309 shares outstanding and lists the approximate sale date as 08/12/2025 on NASDAQ. The shares were acquired as restricted stock awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares) and were paid via Equity Compensation. The filer reports Nothing to Report for securities sold in the past three months and includes the standard representation that no material nonpublic information is known.

Positive

• Full transaction details disclosed: number of shares (33,436), aggregate market value ($304,100.00), broker and proposed sale date (08/12/2025).
• Acquisition transparency: shares were acquired as Restricted Stock Awards on 03/03/2025 (14,779) and 03/04/2025 (18,657) and paid via Equity Compensation.
• No recent sales reported: the filing states Nothing to Report for securities sold in the past three months.

Negative

• Filer contact/CIK not shown: the provided extract does not include populated filer CIK or submission contact details.
• Sale planned shortly after grant: shares were granted in early March 2025 with a proposed sale date of 08/12/2025, indicating disposition within months of acquisition.
• Insider sale size relative to outstanding shares is small: 33,436 shares represent approximately 0.0106% of 314,079,309 shares outstanding (calculated from filing figures).

Insights

Securities Analyst

TL;DR: Routine insider sale notice disclosing 33,436 shares worth $304,100, acquired as restricted stock awards in March 2025.

The Form 144 identifies a proposed sale of 33,436 Common Class A shares via Charles Schwab with an aggregate market value of $304,100 and an approximate sale date of 08/12/2025 on NASDAQ. The filing shows acquisition dates of 03/03/2025 and 03/04/2025 as restricted stock awards paid via equity compensation and reports no securities sold in the prior three months. This filing is informational and, on its face, is a routine disclosure of an intended sale rather than an indicator of company-level changes.

Corporate Governance Expert

TL;DR: Governance filing is complete on transaction details but lacks some filer contact identifiers in the visible content.

The notice provides material transaction details including number of shares, aggregate market value, broker name and address, acquisition method and dates, and the exchange for the proposed sale. The filing also contains the signer representation about absence of undisclosed material information. The visible content does not include explicit filer CIK or contact fields populated in the provided extract, which are typically expected for traceability.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Class A	Charles Schwab Corporation 3000 Schwab Way Westlake TX 76262	33436	304100.00	314079309	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Class A	03/03/2025	Restricted Stock Award	Issuer			14779	03/03/2025	Equity Compensation
Common Class A	03/04/2025	Restricted Stock Award	Issuer			18657	03/04/2025	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Amneal (AMRX) Form 144 disclose?

The filing discloses a proposed sale of 33,436 Common Class A shares with an aggregate market value of $304,100.00, to be sold via Charles Schwab on 08/12/2025 on NASDAQ.

When and how were the shares that AMRX plans to sell acquired?

The shares were acquired as Restricted Stock Awards from the issuer on 03/03/2025 (14,779 shares) and 03/04/2025 (18,657 shares), paid via Equity Compensation.

Does the Form 144 report any sales in the past three months for AMRX?

No. The filing states Nothing to Report for securities sold during the past three months by the person for whose account the securities are to be sold.

Which broker is handling the proposed AMRX sale?

The broker listed is Charles Schwab Corporation at 3000 Schwab Way, Westlake, TX 76262.

What representation does the filer make about material nonpublic information?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.